AstraZeneca

About AstraZeneca

AstraZeneca is a global, science-led pharmaceutical company focused on developing medicines that address a range of health conditions. Its work spans several therapeutic areas, including cancer, cardiovascular and metabolic diseases, respiratory conditions, and rare diseases. The company aims to advance healthcare through scientific research and innovation.

In diabetes care, AstraZeneca's portfolio includes Forxiga, which contains dapagliflozin, and Xigduo XR, a combination medicine containing dapagliflozin and metformin. These products are used in the management of type 2 diabetes according to their approved product information and the patient's clinical needs.

Popular AstraZeneca Products

The AstraZeneca products listed in this catalogue include:

• Forxiga 5 mg – contains dapagliflozin.

• Forxiga 10 mg – contains dapagliflozin.

• Xigduo XR 10/1000 mg – contains dapagliflozin and metformin in an extended-release formulation.

These products contain different active ingredients or strengths, so they should not be treated as interchangeable. Availability and approved uses can differ between countries.

Understanding Forxiga and Dapagliflozin

Forxiga contains dapagliflozin, a medicine belonging to a class known as sodium-glucose cotransporter 2 (SGLT2) inhibitors. It works by helping the kidneys remove glucose through the urine. Depending on the country's approved product information, dapagliflozin may be prescribed for type 2 diabetes and certain heart or kidney conditions.

Forxiga is listed in the 5 mg and 10 mg strengths in this catalogue. The appropriate strength and whether the medicine is suitable depend on the individual's health, kidney function, other medicines, and the prescribing clinician's assessment.

What Is Xigduo XR 10/1000 mg?

Xigduo XR combines dapagliflozin with metformin in an extended-release tablet. The two ingredients work in different ways to support blood glucose management in people with type 2 diabetes. Dapagliflozin helps the body remove glucose through urine, while metformin reduces glucose production by the liver and helps the body respond to insulin. The extended-release formulation is designed to release metformin over time.

The 10/1000 mg strength listed here contains 10 mg of dapagliflozin and 1000 mg of metformin. It is a combination prescription medicine, and its suitability depends on the patient's treatment history, kidney function, and other clinical factors.

Forxiga vs Xigduo XR: What Is the Difference?

The main difference is the active ingredients. Forxiga contains dapagliflozin alone, while Xigduo XR combines dapagliflozin with metformin. Although both contain dapagliflozin, they have different formulations and should only be used as prescribed.

A clinician may consider a single-ingredient medicine or a combination treatment based on the patient's current medicines, blood glucose control, tolerance, and medical history. Patients should not switch between these products or change strengths without professional guidance.

Important Safety Information

Forxiga and Xigduo XR are prescription medicines. Their suitability should be assessed by a qualified healthcare professional, including consideration of kidney function and other medical conditions.

Dapagliflozin-containing medicines may increase the risk of dehydration, genital fungal infections, and certain urinary or metabolic complications. Metformin-containing medicines also carry specific precautions, including the rare but serious risk of lactic acidosis in susceptible patients.

Seek medical advice about possible side effects, interactions, warning signs, and monitoring requirements. Follow the product leaflet approved for your country and do not start, stop, or change treatment without consulting your prescriber.